Sage Therapeutics to Report Second Quarter 2017 Financial Results on Thursday, August 3, 2017
July 20 2017 - 4:10PM
Business Wire
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage
biopharmaceutical company developing novel medicines to treat
life-altering central nervous system (CNS) disorders, today
announced that the company will host a conference call and live
webcast on Thursday, August 3, 2017 at 4:30 pm ET to report its
second quarter 2017 financial results and to discuss recent
business updates.
The live webcast can be accessed on the investor page of Sage's
website at investor.sagerx.com. The conference call can be
accessed by dialing 1-866-450-8683 (toll-free domestic) or
1-281-542-4847 (international) and using the conference ID
58436410. A replay of the webcast will be available on Sage's
website approximately two hours after the completion of the event
and will be archived for up to 30 days.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical
company committed to developing novel medicines to transform the
lives of patients with life-altering central nervous system (CNS)
disorders. Sage has a portfolio of novel product candidates
targeting critical CNS receptor systems, GABA and NMDA. Sage's lead
program, SAGE-547, is in Phase 3 clinical development for
super-refractory status epilepticus, a rare and severe seizure
disorder, and for postpartum depression. Sage is developing its
next generation modulators, including SAGE-217 and SAGE-718, in
various CNS disorders. For more information, please
visit www.sagerx.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170720006004/en/
Investor Contact:Sage TherapeuticsPaul Cox,
617-299-8377paul.cox@sagerx.comorMedia Contact:Suda
Communications LLCMaureen L. Suda,
585-387-9248maureen.suda@sagerx.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Apr 2023 to Apr 2024